Optima Clinic - Centrum Medyczne’s Post

Well presented Dovato to Biktarvy switch study GESIDA 11920 evaluating neuropsychiatric & cognitive co-morbidities. 24 weeks follow-up. Pre-presentation thought: Not sure I agree with the premise that DTG is less well tolerated in this regard as Gilead's own study, GS-1490, showed that when both are combined with a tenofovir-AF/emtrictabine backbone, there was no difference in tolerability. People had been on DTG/3TC for a median of 2 years. 3/41 and 2/39 on Dovato and Biktarvy respectively discontinued for CNS adverse events. No significant differences in patient reported outcomes. Better GI tolerability on Biktarvy (that's interesting, my anecdotal experience is that some people do better off tenofovir, whether it's -DF or -AF). However, I wonder if this was sufficiently powered and, if the difference was real, why it was not evident at W12 too? Post-presentation thoughts: there is no important CNS difference between dolutegravir and bictegravir unless dolutegravir is combined with abacavir. #HIVglasgow #hivglasgow2024 Gilead Sciences ViiV Healthcare British HIV Association (BHIVA)

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐧𝐞𝐰 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐭𝐫𝐚𝐧𝐬𝐩𝐥𝐚𝐧𝐭 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞! An observational study published this week in The New England Journal of Medicine reveals that kidney transplant recipients with HIV who receive organs from HIV-positive donors experience similar safety outcomes as those receiving organs from HIV-negative donors. These findings support the proposed expansion of such transplants beyond the current research-only settings, potentially broadening access and improving patient outcomes. #TransplantMedicine #HIVResearch #KidneyTransplant #OrganDonation #MedicalResearch 

Neuroinflammation generated by HIV-infected microglia promotes dysfunction and death of neurons in human brain organoids Despite the success of combination antiretroviral therapy (ART) for HIV, mild forms of HIV-associated neurocognitive disorder (HAND) persist. Research highlights that brain microglia are principal targets for HIV infection. Using advanced pluripotent stem cell-derived brain organoid models, it was found that HIV infection in microglia triggers significant increases in inflammatory chemokines (CCL2, CXCL10) and type I interferon-stimulated genes, even after ART treatment. Inflammation spreads to uninfected bystander neurons, leading to their dysfunction and death. These findings emphasize the need for targeted therapies to address HAND and improve neurological outcomes for individuals with HIV. link: https://lnkd.in/de9wEbz3 #HIVResearch #Neuroinflammation #HAND #Microglia #StemCellResearch #Neurodegeneration

A recent study led by Kristine Erlandson, MD, shines as a beacon of hope. Living with HIV poses unique challenges, and among them is the heightened risk of fatty liver disease, a condition with potentially severe consequences. However, Dr. Erlandson and her team have uncovered a game-changing discovery: repurposing a well-known weight-loss drug may hold the key to combating this prevalent issue. Dr. Erlandson's research is not only advancing medical science but also reshaping our understanding of aging with HIV. As life expectancy for individuals with HIV continues to rise, addressing age-related health challenges becomes paramount. Her work underscores the need for tailored approaches to care, empowering individuals to lead fulfilling lives well into the future. Check out the full story below! #HIVResearch #medicine #medicalresearch https://bit.ly/44KetWL

Exploring the Realities of Neuropathic Pain Among HIV Patients 🔬 In-Depth Study Insight Led by Whitney Scott, Maite Garcia Calderon Mendoza Del Solar, Harriet Kemp, Lance McCracken, Amanda C de C Williams, Andrew S C Rice, a groundbreaking qualitative study investigates the nuanced experiences of neuropathic pain in people living with HIV. Through detailed interviews with 26 individuals, this research offers unprecedented insight into the daily challenges and the broader impact of this condition. 💡 Study Highlights Complex Pain Experience: Participants described neuropathic pain as unusually perplexing and often misdiagnosed. Impact on Life: The pain significantly disrupts emotional health, social interactions, and overall functionality. Struggle for Relief: Efforts to manage pain are complicated by the dual challenges of HIV-related stigma and the inefficacy of conventional treatments. 🌟 Importance of Psychosocial Support The findings emphasize the importance of integrating psychosocial support into treatment plans to address the multifaceted nature of neuropathic pain in HIV patients effectively. 📖 Dive deeper into the impact of neuropathic pain and explore strategies for improvement. 🔗 https://lnkd.in/dEhEzc8f ✨ Earn 1.0 CME Credit by engaging with this content. #HIVAwareness #ChronicPain #MedicalResearch #CME #HealthcareProfessionals #PhysicianInsights

A newly published analysis reveals an additional mechanism behind statin therapy’s heart-related benefits in people with HIV. Investigators who previously found that a daily statin pill helps prevent heart attacks and strokes in people with HIV have now discovered a potential mechanism that may help to stabilize plaques and prevent their rupture in blood vessels. The research is published in JAMA Cardiology. “Individuals with HIV tend to have an excess of noncalcified plaques that are vulnerable to rupture at a younger age, putting them at high risk for strokes, heart attacks, and sudden cardiac death,” said senior author @Steven Grinspoon, MD, chief of the Metabolism Unit at Massachusetts General Hospital, a founding member of the Mass General Brigham health care system. Read more about their findings: https://lnkd.in/gdubXS-y

See This Article in Our Latest HIV Nursing Matters Publication Palliative care for people living with HIV and cancer is becoming increasingly important as advances in antiretroviral therapy allow individuals to live longer. This article explores how the shifting disease landscape has led to rising rates of non-AIDS-defining cancers and highlights the unique challenges of diagnosing and managing cancer in this population. With delayed presentations, socioeconomic barriers, and the interplay of HIV and cancer, the need for palliative care is greater than ever. Find the full version of HIV Nursing Matters November 2024 here: https://lnkd.in/dT5h6yGa #PalliativeCare #HIVCare #CancerCare #HealthcareProfessionals #ChangingLives

📃Scientific paper: Prevalence of obesity, hypertension and diabetes among people living with HIV in South Africa: a systematic review and meta-analysis Abstract: Background HIV has become a manageable chronic condition due to the success and scale-up of antiretroviral therapy (ART). Globally, South Africa has the highest number of people living with HIV (PLHIV) and research evidence indicates that countries with the highest burden of PLHIV have a substantial burden of obesity, hypertension (HPT) and type 2 diabetes (T2D). We sought to summarize the burden of these three common NCDs among PLHIV in South Africa. Methods In this systematic review, multiple databases were searched for articles reporting on the prevalence of obesity, HPT, and T2D among PLHIV in South Africa published since journal inception until March 2022. A meta-analysis was conducted using random-effects models to obtain pooled prevalence estimates of the three NCDs. Heterogeneity was assessed using X^2 test on Cochran’s Q statistic. Results We included 32 studies, with 19, 22 and 18 studies reporting the prevalence of obesity, HPT, and T2D among PLHIV, respectively. The overall prevalence of obesity, HPT, and T2D was 23.2% [95% CI 17.6; 29.9], 25.5% [95% CI 15.6; 38.7], and 6.1% [95% CI 3.8; 9.7] respectively. The prevalence of obesity was significantly higher among women ( P  = 0.034) compared to men, however the prevalence of HPT and T2D did not differ by sex. The prevalence of each of the three NCDs did not differ significantly between rural, urban, and peri-urban areas. The prevalence of obesity and T2D was higher in studies conducted between 2013 and ... Continued on ES/IODE ➡️ https://etcse.fr/8zr7 ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

🌟 Dolutegravir: The Leading Choice for Older HIV Patients! 🌟 Recent research highlights dolutegravir (DTG) as a reliable treatment option for individuals aged 50 and above living with HIV. A comprehensive study involving over 15,700 veterans has demonstrated that DTG-based regimens not only achieve higher virologic suppression but also exhibit lower discontinuation rates compared to other antiretroviral therapies. Key Findings: ✅ DTG shows robust effectiveness, especially in ART-experienced patients. ✅ DRV and RAL regimens face higher rates of treatment discontinuation. ✅ Prioritizing DTG can enhance long-term health outcomes and reduce healthcare costs. Healthcare providers are encouraged to consider DTG-based ART regimens for older patients to ensure better adherence and improved quality of life. For a deeper dive into this pivotal study, click the link! 🔗 #AgingPopulation #AntiretroviralTherapy #Dolutegravir #General #HIV #Healthcare #PatientCare #MarketAccess #MarketAccessToday

🚀 Exciting Breakthrough in #KidneyTransplantation_for_HIV_Patients! 🚀 I’m thrilled to share that our latest research, published in the #NEJM, demonstrates the safety and efficacy of kidney transplantation from donors with HIV to recipients with HIV. This groundbreaking study, conducted across 26 U.S. centers, shows that such transplants are non-inferior to those from donors without HIV, marking a significant step forward in addressing organ shortages and improving outcomes for patients with HIV. https://lnkd.in/eUFPX-SS